We confirmed the MUC2 protein‐suppressive effect of dual drug therapy in explant tissue from KRAS mutated mucinous colon/appendix cancers, demonstrating reduced MUC2 protein (Figure 3B) and mRNA (Figure 3C) expression levels at 24 hours. The gene discussed is MUC2; the disease is appendix cancer.